Marty M - Search Results

1

Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group.

Marty M, Kleisbauer JP, Fournel P, Vergnenegre A, Carles P, Loria-Kanza Y, Simonetta C, de Bruijn KM. Marty M, et al. Anticancer Drugs. 1995 Feb;6 Suppl 1:15-21. Anticancer Drugs. 1995. PMID: 7749165 Clinical Trial.

2

Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.

Marty M. Marty M. Eur J Cancer Clin Oncol. 1989;25 Suppl 1:S41-5. Eur J Cancer Clin Oncol. 1989. PMID: 2533898 Review.

3

A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. The Granisetron Study Group.

Marty M. Marty M. Eur J Cancer. 1992;28A Suppl 1:S12-6. doi: 10.1016/0959-8049(92)90630-k. Eur J Cancer. 1992. PMID: 1320913 Clinical Trial.

4

Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group.

Chevallier B, Marty M, Paillarse JM. Chevallier B, et al. Among authors: marty m. Br J Cancer. 1994 Dec;70(6):1171-5. doi: 10.1038/bjc.1994.467. Br J Cancer. 1994. PMID: 7981071 Free PMC article. Clinical Trial.

5

A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group.

Marty M. Marty M. Eur J Cancer. 1990;26 Suppl 1:S28-32. Eur J Cancer. 1990. PMID: 2169783 Clinical Trial.

6

Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujade-Lauraine E, Paule B, Paes D, Bons J. Marty M, et al. N Engl J Med. 1990 Mar 22;322(12):816-21. doi: 10.1056/NEJM199003223221205. N Engl J Med. 1990. PMID: 2137902 Free article. Clinical Trial.

7

[Antiemetic effect of ondansetron in recurrent chemotherapy with cisplatin].

Marty M, Richard A, d'Allens H. Marty M, et al. Bull Cancer. 1993 Jul;80(7):618-23. Bull Cancer. 1993. PMID: 8204942 French.

8

Future trends in cancer treatment and emesis control.

Marty M. Marty M. Oncology. 1993 May-Jun;50(3):159-62. doi: 10.1159/000227170. Oncology. 1993. PMID: 8459985 Review.

9

GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting.

Marty M, Droz JP, Pouillart P, Paule B, Brion N, Bons J. Marty M, et al. Cancer Chemother Pharmacol. 1989;23(6):389-91. doi: 10.1007/BF00435842. Cancer Chemother Pharmacol. 1989. PMID: 2523762

10

[Chemotherapy-induced nausea and vomiting: from experimentation to experience].

Marty M. Marty M. Bull Cancer. 1996 Dec;83(12):1014-8. Bull Cancer. 1996. PMID: 9116365 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

794 results

Search Page

Filters